These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 27569726)

  • 1. In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores.
    Schwimmer JB; Lavine JE; Wilson LA; Neuschwander-Tetri BA; Xanthakos SA; Kohli R; Barlow SE; Vos MB; Karpen SJ; Molleston JP; Whitington PF; Rosenthal P; Jain AK; Murray KF; Brunt EM; Kleiner DE; Van Natta ML; Clark JM; Tonascia J; Doo E;
    Gastroenterology; 2016 Dec; 151(6):1141-1154.e9. PubMed ID: 27569726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alanine Aminotransferase and Gamma-Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis.
    Newton KP; Lavine JE; Wilson L; Behling C; Vos MB; Molleston JP; Rosenthal P; Miloh T; Fishbein MH; Jain AK; Murray KF; Schwimmer JB;
    Hepatology; 2021 Mar; 73(3):937-951. PubMed ID: 32416645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
    Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.
    Lavine JE; Schwimmer JB; Van Natta ML; Molleston JP; Murray KF; Rosenthal P; Abrams SH; Scheimann AO; Sanyal AJ; Chalasani N; Tonascia J; Ünalp A; Clark JM; Brunt EM; Kleiner DE; Hoofnagle JH; Robuck PR;
    JAMA; 2011 Apr; 305(16):1659-68. PubMed ID: 21521847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial.
    Janczyk W; Lebensztejn D; Wierzbicka-Rucińska A; Mazur A; Neuhoff-Murawska J; Matusik P; Socha P
    J Pediatr; 2015 Jun; 166(6):1358-63.e1-3. PubMed ID: 25771388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease.
    Middleton MS; Van Natta ML; Heba ER; Alazraki A; Trout AT; Masand P; Brunt EM; Kleiner DE; Doo E; Tonascia J; Lavine JE; Shen W; Hamilton G; Schwimmer JB; Sirlin CB;
    Hepatology; 2018 Mar; 67(3):858-872. PubMed ID: 29028128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis.
    Wah Kheong C; Nik Mustapha NR; Mahadeva S
    Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1940-1949.e8. PubMed ID: 28419855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
    Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
    J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.
    Mansoor S; Yerian L; Kohli R; Xanthakos S; Angulo P; Ling S; Lopez R; Christine CK; Feldstein AE; Alkhouri N
    Dig Dis Sci; 2015 May; 60(5):1440-7. PubMed ID: 25540086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
    Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
    JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
    Harrison SA; Neff G; Guy CD; Bashir MR; Paredes AH; Frias JP; Younes Z; Trotter JF; Gunn NT; Moussa SE; Kohli A; Nelson K; Gottwald M; Chang WCG; Yan AZ; DePaoli AM; Ling L; Lieu HD
    Gastroenterology; 2021 Jan; 160(1):219-231.e1. PubMed ID: 32781086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of l-carnitine supplementation on children and adolescents with nonalcoholic fatty liver disease (NAFLD): a randomized, triple-blind, placebo-controlled clinical trial.
    Saneian H; Khalilian L; Heidari-Beni M; Khademian M; Famouri F; Nasri P; Hassanzadeh A; Kelishadi R
    J Pediatr Endocrinol Metab; 2021 Jul; 34(7):897-904. PubMed ID: 33939897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis.
    Armas D; Holt RJ; Confer NF; Checani GC; Obaidi M; Xie Y; Brannagan M
    Adv Ther; 2018 Feb; 35(2):199-209. PubMed ID: 29411268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease.
    Lin CH; Kohli R
    Curr Gastroenterol Rep; 2020 Aug; 22(10):52. PubMed ID: 32814993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
    Harrison SA; Alkhouri N; Davison BA; Sanyal A; Edwards C; Colca JR; Lee BH; Loomba R; Cusi K; Kolterman O; Cotter G; Dittrich HC
    J Hepatol; 2020 Apr; 72(4):613-626. PubMed ID: 31697972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease.
    Dohil R; Schmeltzer S; Cabrera BL; Wang T; Durelle J; Duke KB; Schwimmer JB; Lavine JE
    Aliment Pharmacol Ther; 2011 May; 33(9):1036-44. PubMed ID: 21395631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease.
    Shiffman M; Freilich B; Vuppalanchi R; Watt K; Chan JL; Spada A; Hagerty DT; Schiff E
    Aliment Pharmacol Ther; 2019 Jan; 49(1):64-73. PubMed ID: 30430605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease.
    Pacifico L; Bonci E; Di Martino M; Versacci P; Andreoli G; Silvestri LM; Chiesa C
    Nutr Metab Cardiovasc Dis; 2015 Aug; 25(8):734-41. PubMed ID: 26026214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice.
    Xanthakos SA; Lavine JE; Yates KP; Schwimmer JB; Molleston JP; Rosenthal P; Murray KF; Vos MB; Jain AK; Scheimann AO; Miloh T; Fishbein M; Behling CA; Brunt EM; Sanyal AJ; Tonascia J;
    Gastroenterology; 2020 Nov; 159(5):1731-1751.e10. PubMed ID: 32712103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.